Cannabis Law Report

JANUARY 4, 2022

AUSTIN, Texas–(BUSINESS WIRE)–Anebulo Pharmaceuticals, Inc. I am so very proud of all Anebulo has achieved over the past 18 months, including building out a highly effective team, securing new intellectual property protection, preparing and starting a proof-of-concept clinical trial, advancing regulatory discussions with the U.S.

Pharmaceutical 52

Pharmaceutical Research and Development Clinical Trials Cannabinoids 52

Cannabis Law Report

DECEMBER 1, 2021

BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan by delaying aging, today announced that it will participate in two investor conferences during the month of December 2021. About Supera-CBD.

Pharmaceutical 52

Pharmaceutical Clinical Trials Chronic Pain Therapy 52

Cannabis Law Report

AUGUST 7, 2021

The results of our successful pivotal Phase 3 clinical trial were recently published in Nature Medicine and profiled on the front page of The New York Times. We are pioneering a new kind of pharmaceutical company that prioritizes public benefit and is committed to sustainability, accountability, and transparency.

Clinical Trials 105

Clinical Trials Research and Development Compliance Compliance 105

Cannabis Law Report

NOVEMBER 16, 2021

Phase 2 trial recruiting begins immediately; efficacy data expected by the end of the first quarter of 2022. BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. About MyMD Pharmaceuticals, Inc. MyMD Pharmaceuticals, Inc. tumor necrosis factor receptor I (TNFRI) and IL-6.

Pharmaceutical 52

Pharmaceutical Clinical Trials Research and Development Therapy 52

Cannabis Law Report

JANUARY 5, 2022

BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan by delaying aging, announced that the U.S. About MyMD Pharmaceuticals, Inc. MyMD Pharmaceuticals, Inc.

Pharmaceutical 52

Pharmaceutical Clinical Trials Therapy Treatment 52

Cannabis Law Report

NOVEMBER 23, 2021

BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan by delaying aging, announced that the U.S. About MyMD Pharmaceuticals, Inc. MyMD Pharmaceuticals, Inc.

Pharmaceutical 52

Pharmaceutical Clinical Trials Therapy Chronic Pain 52

MMJ Recs

APRIL 1, 2024

Furthermore, ongoing clinical trials are investigating CBD’s efficacy in treating conditions such as multiple sclerosis, Parkinson’s disease, and substance abuse disorders. CBD Oil for Medical Conditions CBD oil has gained popularity as a versatile and accessible option for managing various medical conditions.

CBD 52

CBD Clinical Trials Chronic Pain Epilepsy 52

Cannabis Law Report

JULY 28, 2021

The Company and Its Subsidiary KGK Science Have Also Completed the Pre-Qualification Audits of Its Canadian Facilities to Enable Clinical Trials in an Arrangement with Aleafia Health. The audits will enable KGK to conduct clinical trials in the areas of psychedelics and nutraceuticals, among other substances of study.

Clinical Trials 81

Clinical Trials Research and Development Treatment Therapy 81

Cannabis Law Report

SEPTEMBER 24, 2019

Here is the BBC report and below you will find the full press release from GW Pharmaceuticals. The medication, developed by GW Pharmaceuticals, will be used in combination with another epilepsy medication called clobazam. What about other medical cannabis products? There are many different medical cannabis products. .

Pharmaceutical 55

Pharmaceutical Epilepsy Research and Development Medicine 55

Cannabis Law Report

DECEMBER 5, 2021

The Multidisciplinary Association for Psychedelic Studies (MAPS) and Vine Ventures have announced the creation of a novel, social impact Special Purpose Vehicle (SPV), called the Regenerative Financing Vine (RFV), that will infuse $70 million into patient access infrastructure and research for MDMA-assisted therapy for PTSD.

Therapy 52

Therapy Access Research and Development Clinical Trials 52

The Cannigma

JUNE 14, 2021

‘Junk’ cannabis ‘ill-suited for clinical trials’. The cannabis grown at the University of Mississippi “is junk, ill-suited for clinical trials, and genetically closer to hemp than the marijuana available from dispensaries and used by Americans nationwide,” according to the lawsuit. Shutterstock).

DEA 133

DEA Research and Development Clinical Trials Pharmaceutical 133

Cannabis Law Report

JULY 28, 2021

This includes First Time in Human (“FTiH”) clinical trials, which are expected to commence in 2022, for the Group’s lead compound OCT461201, a selective cannabinoid receptor type 2 (“CB2”) agonist with initial indications in the areas of post herpetic neuralgia and visceral pain caused by irritable bowel syndrome.

Cannabinoids 105

Cannabinoids Clinical Trials Safety Medicine 105

Cannabis Law Report

JANUARY 13, 2020

12, 2020 (GLOBE NEWSWIRE) — GW Pharmaceuticals plc (Nasdaq: GWPH), the world leader in the science, development, and commercialization of cannabinoid prescription medicines, today reported preliminary, unaudited net product sales for the fourth quarter and full-year 2019 and key priorities for 2020. Enquiries: GW Pharmaceuticals plc.

Pharmaceutical 66

Pharmaceutical Clinical Trials Research and Development Programs 66

Cannabis Law Report

NOVEMBER 19, 2021

It has been designated a Breakthrough Therapy by the FDA and the results of our pivotal Phase 3 clinical trial were published in Nature Medicine or profiled on the front page of The New York Times. MAPS PBC strives to establish a supportive, equitable and accessible work environment. European Regulatory Lead Executive Summary.

Clinical Trials 52

Clinical Trials Research and Development Therapy Compliance 52

Canna Law Blog

NOVEMBER 10, 2020

We discussed how licensed facilities won’t be up and running for a few more years, and how, in the meantime, people will have to make do with general decriminalization under Measure 109 and maybe, in certain cases, reliance on Right to Try access. It’s quite restrictive. Or, it could be because FDA is sort of a drag about everything.

Therapy 79

Therapy Clinical Trials Decriminalization Patients 79

Cannabis Law Report

OCTOBER 2, 2021

The results of our successful pivotal Phase 3 clinical trial were recently published in Nature Medicine and profiled on the front page of The New York Times. We are pioneering a new kind of pharmaceutical company that prioritizes public benefit and is committed to sustainability, accountability, and transparency.

Clinical Trials 52

Clinical Trials Research and Development Compliance Compliance 52

Cannabis Law Report

SEPTEMBER 8, 2021

Key Transaction Details: The Valens Company, a leading Canadian manufacturer of cannabis products, has entered into a long-term partnership with Epsilon, for exclusive access to the Epsilon’s GMP Manufacturing Facility in Southport , Queensland Australia (the “ Southport Facility ‘).

Access 97

Access Research and Development Medicine THC 97

NewsMunchies

NOVEMBER 12, 2021

Psilocybin is the active ingredient found in magic mushrooms and research suggests it has the potential to treat various mental illnesses and is safer than pharmaceutical drugs and alcohol, which can be habit-forming. Additional clinical trials underway in the U.S. and Europe are aimed at winning regulatory approval.

Clinical Trials 90

Clinical Trials Therapy Decriminalization DEA 90

Cannabis Law Report

NOVEMBER 7, 2021

The committee has been formed to expand the company’s pharmaceutical expertise and accelerate R&D, product development and clinical trials ahead of a potential NASDAQ listing. The committee will also enable CPH to accelerate R&D, product development and other clinical trials ahead of its potential NASDAQ listing.

Medicine 52

Medicine Clinical Trials Research and Development Pharmaceutical 52

Cannabis Law Report

APRIL 21, 2022

The availability of larger quantities of cGMP-compliant MDMA will facilitate ongoing clinical trials and provide for future therapeutic use following anticipated regulatory approvals. Publication of this process establishes “prior art,” contributing to MAPS’ patient access strategy by making intellectual property public .

Clinical Trials 52

Clinical Trials Research and Development Therapy Media 52

Cannabis Law Report

FEBRUARY 5, 2022

5+ years’ experience in pharmaceutical industry preferably prescription medicines, narcotics, experimental drugs or products supplied via access schemes. Experience with prescription drug registration submissions and lifecycle management, including clinical trial activities. Experience in project management.

Medicine 52

Medicine Research and Development Clinical Trials Pharmaceutical 52

Canna Law Blog

NOVEMBER 27, 2021

In fact, Small Pharma has been conducting trials as reported by the BBC and expanded its clinical trial this past summer. Several months ago, Canada-based Algernon Pharmaceuticals submitted a request to U.S. regulators to launch a clinical program to study the use of DMT for the treatment of stroke-related dysfunction.

Therapy 88

Therapy Clinical Trials DEA Microdosing 88

Cannabis Law Report

DECEMBER 15, 2021

5+ years’ experience in pharmaceutical industry preferably prescription medicines, narcotics, experimental drugs or products supplied via access schemes. Experience with prescription drug registration submissions and lifecycle management, including clinical trial activities. Experience in project management.

Medicine 52

Medicine Research and Development Clinical Trials Pharmaceutical 52

Cannabis Law Report

JULY 24, 2021

The groundbreaking progress that we’ve seen from the Multidisciplinary Association for Psychedelic Studies (MAPS) in its Phase 3 clinical trials of MDMA-assisted psychotherapy for Post-Traumatic Stress Disorder (PTSD), including receiving Breakthrough Therapy Designation from the Food and Drug Administration (FDA), shows great promise to date.

Research and Development 105

Research and Development Clinical Trials Therapy Events 105

Cannabis Law Report

SEPTEMBER 12, 2022

Our mushrooms are some of the most tested products on the planet as we cross the lines between Pharmaceutical, Agriculture, Botanical, and Food testing quality assays,” said Optimi Chief Science Officer, Justin Kirkland. To access a complete photo gallery of this historic grow, please click here. Penis Envy. Blue Pulaski.

History 52

History Clinical Trials Legalization Research and Development 52

The Cannigma

APRIL 12, 2023

Cannabis is often reported to help people reduce the number of pharmaceuticals they’re taking, and this trend continues in this study. Sleep is not often the focus of clinical trials on cannabis; rather it is often a secondary outcome. Has CBN been proven to help with sleep? This CBN study is one such example.

Sleep 133

Sleep Data Tincture Research and Development 133

Cannabis Law Report

NOVEMBER 19, 2021

It has been designated a Breakthrough Therapy by the FDA and the results of our pivotal Phase 3 clinical trial were published in Nature Medicine or profiled on the front page of The New York Times. MAPS PBC strives to establish a supportive, equitable and accessible work environment. Key Responsibilities. Position Requirements.

Research and Development 52

Research and Development Clinical Trials Therapy Pharmaceutical 52

Cannabis Law Report

NOVEMBER 22, 2019

. “As MMJ International Holdings continues to advance to its clinical trials, a specialty pharmaceutical solutions company will be supporting MMJ with the FDA, DEA required development API and specialized liquid encapsulation solutions,” said Elio Mariani, PhD, EVP of Research & Development.

DEA 66

DEA Clinical Trials THC Research and Development 66

Cannabis Law Report

MARCH 29, 2022

Mullette joins MAPS PBC after more than 20 years in the pharmaceutical industry. Prior to his work at Moderna, Mullette developed broad pharmaceutical expertise with Sanofi in a variety of management roles in the U.S., Mullette joins MAPS PBC after more than 20 years in the pharmaceutical industry. He holds a B.S.

Therapy 52

Therapy Pharmaceutical Clinical Trials Access 52

Cannabis Law Report

SEPTEMBER 1, 2021

The company recently became the industry’s first firm to list on the NYSE American exchange and their psilocybin clinical trial for depression is making excellent progress. Doug Drysdale is an experienced director, having been CEO and chairman of the board of Nasdaq-listed companies and pharmaceutical firms.

Research and Development 102

Research and Development Therapy Clinical Trials Pharmaceutical 102

Cannabis Law Report

APRIL 21, 2022

Commercialization & Patient Access · Any City, Any State, California. It has been designated a Breakthrough Therapy by the FDA and the results of our pivotal Phase 3 clinical trial were published in Nature Medicine and profiled on the front page of The New York Times. About MAPS Public Benefit Corporation (MAPS PBC).

Advocacy 52

Advocacy Therapy Clinical Trials Environment 52

Cannabis Law Report

JUNE 21, 2021

Pharmaceutical companies use artificial intelligence (AI) to sort through reams of scientific data to find potentially effective active ingredients to be developed into approved drugs. But if that doctor has access to information from 40,000 patients it’s a different story.

Data 105

Data Clinical Trials Research and Development Indica 105

Cannabis Law Report

FEBRUARY 10, 2022

A look at key research and clinical trials that were published in 2021, with analysis of themes like microdosing and SSRI interactions. Access the PDF here. We tried to maintain a balanced view, with a primary focus on research and trials as well as drug policy reform and other contextual factors. and Canada.

Clinical Trials 52

Clinical Trials Microdosing Pharmaceutical Policy 52

Cannabis Law Report

JANUARY 11, 2022

In a recent peer-reviewed study conducted independently by Colorado State University researchers and published in the open-access scientific journal Pharmaceuticals , it was found that Ripple products absorbed into the bloodstream significantly faster (Ripple Gummies 2.3X faster), and Ripple Dissolvables (1.9X

THC 52

THC Clinical Trials Research and Development Sleep 52

Veriheal

MARCH 23, 2023

The people of Japan, a country renowned for its sushi cuisine scene, iconic Mount Fuji, and eye-catching cherry blossom trees, may soon have access to legal medicinal marijuana for intractable diseases. Japan’s latest Cannabis Control Law revisions would apply to pharmaceutical-grade medicinal cannabis products.

Legalization 81

Legalization Marijuana Clinical Trials Seed-To-Sale 81

Cannabis Law Report

SEPTEMBER 20, 2021

provides Heritage and subsidiary Opticann the benefits of offering patients access to safe, convenient, and effective CB4 products developed on trusted technology platforms. The products leverage pharmaceutical technology to maximize performance and safety. TORONTO–(BUSINESS WIRE)–Heritage Cannabis Holdings Corp.

Clinical Trials 52

Clinical Trials Pharmaceutical Data Patients 52

Cannabis Law Report

DECEMBER 18, 2019

…MGC Pharmaceuticals has achieved yet another significant milestone with the bio-pharma company this week surpassing more than 1,800 prescribed products of its medicinal cannabis-based pharmaceutical products in Australia, UK, Brazil and Ireland. The West Australian reports. Source: [link].

Research and Development 59

Research and Development Clinical Trials Seed-To-Sale Pharmaceutical 59